Compare Nu Holdings Ltd (NU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nu Holdings Ltd vs BIO-TECHNE Corp — how do they compare? Nu Holdings Ltd trades at $14.39 (market cap $67.58B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Nu Holdings Ltd is far larger — about 6.1× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| NU | TECH | |
|---|---|---|
Market Cap | $67.58B | $11.16B |
Sector | Financials | Health |
52-Week High | $18.76 | $72.12 |
52-Week Low | $11.60 | $43.31 |
Enterprise Value | — | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NU stock trades at $14.39, up 5.89% in the last session, with a bullish technical signal from moving averages and strong fundamental growth. Revenue surged from $3.0B in 2022 to $10.63B in 2025, while net income turned positive to $2.87B. Recent news highlights expansion in Brazil and Mexico, including a new banking license, supporting continued growth momentum.
Outlook remains positive with a consensus price target of $14.98, though risks include rapid credit expansion and increased provisions. The stock offers exposure to Latin America's digital banking growth but faces execution risks in new markets and competitive pressures. Analyst sentiment is bullish with 55% buy ratings.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
